#United States #Henderson #VolitionRx #Hidradenitis Suppurativa #Nu.Q NETs

VolitionRx Implements Nu.Q® NETs for Hidradenitis Suppurativa Management

VolitionRx Limited (NYSE AMERICAN: VNRX), a leading epigenetics firm, recently announced a significant advancement in clinical research with its Nu.Q® NETs assay, marking a transformative step in managing chronic conditions like Hidradenitis Suppurativa (HS). This complex and painful skin disorder affects approximately 1% of the global population, presenting considerable challenges in treatment and patient management.

The Significance of Nu.Q® NETs

In a newly released study, Volition demonstrated the utility of the Nu.Q® NETs assay in patient management for HS. This technology is designed to detect diseases related to NETosis – a process where neutrophils, a type of immune cell, release contents that can damage tissues and lead to inflammation. The assay has already received CE-marking, permitting its clinical use across 27 EU member states, as well as in three European Economic Area countries and the UK.

Insights from the Study

Mr. Remi Rabeuf, the VP of Corporate Alliances and Strategic Partnerships at Volition, expressed excitement over the study's findings, highlighting the potential of personalized medicine in treating HS. He stated, “This research provides a pathway to enhance patient management through tailored approaches.”

Furthermore, the findings underscore that Nu.Q® NETs can aid clinicians in predicting disease progression, guiding treatment choices, and effectively monitoring patients over time, regardless of whether they are dealing with acute or chronic conditions.

Hidradenitis Suppurativa: A Closer Look

Hidradenitis Suppurativa is characterized by painful skin lesions and recurrent flare-ups, which can severely impact a patient's quality of life. Managing this long-term condition is inherently complex due to variability in symptoms and responses to treatment. The need for innovative solutions has been underscored, especially with an increased reliance on biologics, where treatment responses can be notably inconsistent among patients.

According to Professor Evangelos J. Giamarellos-Bourboulis, co-author of the paper and a physician at ATTIKON University General Hospital in Athens, managing HS effectively demands a precision medicine approach. He noted, “There’s a pressing need for biomarkers reflecting disease activity and treatment response, given the expanding array of biological therapies.”

The ability of Nu.Q® NETs to serve as a straightforward blood test that categorizes patients and monitors their responses represents a noteworthy breakthrough.

Market Potential

The market opportunity for effective disease management solutions like Nu.Q® NETs is substantial, with a Total Addressable Market estimated at $3.8 billion. VolitionRx is committed to optimizing testing methods that are both accessible and affordable, aimed at enhancing patient outcomes.

Conclusion

As VolitionRx continues to advance its research and development initiatives, the implications of the Nu.Q® NETs assay could spell significant changes in chronic disease management, particularly for Hidradenitis Suppurativa patients. By focusing on personalized medicine and unique biomarkers, VolitionRx is paving the way towards a future of more effective and targeted healthcare solutions.

For more detailed insights, the comprehensive study is accessible via MedRXIV here.

Media inquiries regarding this groundbreaking study can be directed to Louise Batchelor at VolitionRx.